Start with the recommended serving size on the label
Key Findings 1 Tirzepatide reduced major kidney events by 23% vs dulaglutide Events: 6.0% vs 7.6% HR 0.77 (95% CI 0.680.88), p=0.0002 The risk of the primary composite kidney outcomewas 23% lower with tirzepatide than with dulaglutide. 2 Benefits were consistent across CKD risk categories Lowtomoderate risk CKD: HR 0.70 Highrisk CKD: HR 0.79 3 Mechanistic drivers differed by CKD stage Lowtomoderate CKD: Less newonset macroalbuminuria Highrisk CKD: Slower eGFR decline This was primarily driven by a lower rate of new-onset persistent macroalbuminuria and a lower rate of eGFR decline. 4 eGFR decline was significantly slower with tirzepatide Overall difference: +0.29 mL/min/1.73 m per year Highrisk CKD: +0.93 mL/min/1.73 m per year 5 Albuminuria improved more with tirzepatide At 36 months, UACR reductions were greater across CKD categories
Users who follow a structured tirzepatide diet plan with attention to meal timing consistently report better sleep than those who eat without regard to when their last meal occurs
[DOI] [PMC free article] [PubMed] [Google Scholar] 60.Christensen-Quick A., Lafferty M., Sun L., Marchionni L., DeVico A., Garzino-Demo A
Among many provisions, the bill will implement federal community engagement requirements for certain able-bodied adults
First Volunteer Receives Experimental Bundibugyo Vaccine health-wellness Can Hepatitis Be Completely Cured
